-
Product Insights
NewNet Present Value Model: Pepgen Inc’s PGN-EDODM1
Empower your strategies with our Net Present Value Model: Pepgen Inc's PGN-EDODM1 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PGN-EDODM1 in Myotonic Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PGN-EDODM1 in Myotonic Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PGN-EDODM1 in Myotonic Dystrophy Drug Details: PGN-EDODM1 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tofacitinib in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tofacitinib in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tofacitinib in Ulcerative Colitis Drug Details: Tofacitinib (PGN-600) is under development for...
-
Product Insights
Gaz-System/ PGN/ Szczecin and Swinoujscie Seaports – Polskie LNG Terminal Expansion – West Pomeranian Voivodeship
Equip yourself with the essential tools needed to make informed and profitable decisions with our Gaz-System/ PGN/ Szczecin and Swinoujscie Seaports - Polskie LNG Terminal Expansion - West Pomeranian Voivodeship report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash...
-
Product Insights
Pelabuhan Indonesia III/ Perusahaan Gas Negara/ PT PGN LNG – Lamong Bay LNG Terminal – East Java
Equip yourself with the essential tools needed to make informed and profitable decisions with our Pelabuhan Indonesia III/ Perusahaan Gas Negara/ PT PGN LNG - Lamong Bay LNG Terminal - East Java report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our...
-
Company Profile
NewBiora Therapeutics Inc – Company Profile
Biora Therapeutics Inc (Biora Therapeutics), formerly Progenity Inc, is a biotechnology company. It develops oral biotherapeutics to replace injection with needle-free. The company's pipeline products portfolio includes PGN-600 and PGN-001 liquid formulations delivered with the drug delivery system for the treatment of ulcerative colitis; liquid formulation of anti-TNF-alpha monoclonal antibody delivered with the oral biotherapeutics delivery system for the treatment of autoimmune conditions; and liquid formulation. It develops smart capsule platforms recoverable sampling systems and PIL Dx for GI sampling...
Add to Basket -
Company Profile
PT Perusahaan Gas Negara (Persero) Tbk – Company Profile
PT Perusahaan Gas Negara (Persero) Tbk (PGN) is a downstream energy that transmits and distributes natural gas. The company plans, constructs and develops downstream natural gas businesses and carries out processing, transportation, storage, and trading of natural gas. It produces, trades, and supplies manufactured artificial gas (hydrocarbon gas), and offers transmission, construction, and maintenance services. Through its subsidiaries, it also operates natural gas supporting businesses which include upstream exploration, downstream processing, construction and terminal regasification and floating storage. The company...
Add to Basket -
Product Insights
Biora Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Biora Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Biora Therapeutics Inc (Biora Therapeutics), formerly Progenity Inc, is a biotechnology company. It develops oral biotherapeutics to replace injection with needle-free. The company's pipeline products portfolio includes PGN-600 and PGN-001 liquid formulations delivered with the drug delivery system for the treatment of ulcerative colitis; PGN-OB1 liquid formulation of anti-TNF-alpha monoclonal antibody delivered with the oral biotherapeutics delivery system for...
-
Product Insights
Dystrophin (DMD) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dystrophin is a cytoplasmic protein, which anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It also acts as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. The Dystrophin - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Dystrophin, complete with...
-
Product Insights
Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Duchenne Muscular Dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and...